Harrow Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HROW research report →
Range $45 – $45
Price Chart
About the company
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation.
- CEO
- Mark L. Baum
- IPO
- 2007
- Employees
- 373
- HQ
- Nashville, TN, US
Get TickerSpark's AI analysis on HROW
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.14B
- P/E
- -42.28
- Fwd P/E
- 20.59
- PEG
- 0.67
- P/S
- 3.98
- P/B
- 41.28
- EV/EBITDA
- 85.61
- Div Yield
- 0.00%
- Gross Margin
- 73.51%
- Op Margin
- 0.80%
- Net Margin
- -9.39%
- ROE
- -90.77%
- ROIC
- 0.74%
Latest fiscal year · YoY change
- Revenue
- $272.30M+36.4%
- Gross Profit
- $204.37M+35.9%
- Op Income
- $38.61M
- Net Income
- $-5,139,000+70.6%
- EPS
- $-0.14+71.4%
- OCF Growth
- +297.6%
- FCF Growth
- +170.2%
- 52W High
- $54.85
- 52W Low
- $25.76
- 50D MA
- $30.22
- 200D MA
- $37.22
- Beta
- 0.24
- RSI (14)
- 61
- Avg Volume
- 619.25K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Harrow posted record third-quarter revenue and sharply improved profitability, while reaffirming full-year sales guidance and raising confidence in a very strong fourth quarter.· November 10, 2026
- Q3 revenue hit a record $99.3 million, up 41% sequentially and 39% year over year.
- Branded revenue was $83.5 million, or about 84% of total revenue, led by VEVYE, IHEEZO and TRIESENCE.
- GAAP gross margin was 75%, flat versus a year ago and up from 71% in Q2; adjusted EBITDA improved to $21.2 million from a $1.2 million loss in Q2.
- Management reaffirmed full-year revenue guidance of $350 million to $365 million and now expects Q4 revenue of roughly $136 million to $151 million.
- The company lowered full-year adjusted EBITDA guidance to more than $40 million, citing lower-than-expected first-half revenue, lower gross margins, and added Q4 spending on G-MELT, QUELL, TRIESENCE and TYRVAYA integration.
Third-quarter revenue was a record $99.3 million, up 41% sequentially and 39% year over year. Branded revenue was $83.5 million, up about 62% year over year, and compounded revenue was $15.8 million. Product revenue included VEVYE at $39.7 million, IHEEZO at $25.3 million, and TRIESENCE at $10.7 million. GAAP gross margin was 75%, versus 71% in Q2 and flat year over year. SG&A was $53.1 million, R&D was $10.3 million, GAAP net income was $9.8 million, adjusted EBITDA was $21.2 million versus an adjusted EBITDA loss of $1.2 million in Q2, and cash and cash equivalents ended at $75.3 million. For the full year, Harrow reaffirmed revenue guidance of $350 million to $365 million and said Q4 revenue should be roughly $136 million to $151 million, implying 37% to 52% sequential growth. The company updated full-year adjusted EBITDA guidance to more than $40 million, with more than $33 million expected in Q4.
Mark Baum said the quarter showed that Harrow is converting demand into revenue and that the second half is unfolding as expected. He emphasized stronger commercial execution, a reorganized sales force built around four focused teams, and HarrowRx as a single access point for the portfolio. His tone was upbeat and increasingly confident, saying the company is shifting from building the platform to delivering financial results, and he repeatedly pointed to a very strong Q4 and momentum into 2027.
Andrew Boll said Q3 was a record revenue quarter and that profitability improved sharply, with adjusted EBITDA of $21.2 million and gross margin of 75%. He explained that gross margins remain below expectations because of mix and lower-margin compounding revenue, while SG&A stayed roughly flat at $53.1 million and R&D rose to $10.3 million due to accelerated work on G-MELT, IHEEZO and TRIESENCE studies. He also noted a one-time $5 million gain from settling litigation with OSRX and said the company ended the quarter with $75.3 million in cash. On guidance, he reaffirmed revenue but cut full-year adjusted EBITDA expectations to more than $40 million because of a weak first half, lower margins, and higher Q4 expenses tied to filings, clinical work and TYRVAYA integration.
Analysts pressed on VEVYE economics, including the impact of business-rule changes and whether the new coverage win will help offset seasonality; management said economics are improving, covered prescriptions are rising, and the new coverage should not create the same first-quarter drag seen earlier this year. Questions on BYOOVIZ focused on why early orders were broad but shallow and how that informs OPUVIZ; management said customers are still validating reimbursement and buy-and-bill economics, but follow-through orders are now coming in and lessons from BYOOVIZ should help the 2027 launch. On QUELL, analysts asked whether another study is needed and what the primary-endpoint miss means; management said there are no current plans for another study, but the data still supports medical messaging and possible label work because the secondary findings on post-procedure pain, ocular surface staining and adverse events were favorable.
The bull case from the call is that Harrow is showing strong commercial leverage: VEVYE, IHEEZO and TRIESENCE all posted meaningful growth, and management believes Q4 will be the strongest quarter in company history. The company also has multiple growth drivers layered in, including TYRVAYA, expanded coverage for VEVYE, and new clinical evidence to support IHEEZO and TRIESENCE.
The biggest risk highlighted on the call is that profitability is still below prior expectations, forcing Harrow to cut full-year adjusted EBITDA guidance despite reaffirming revenue. QUELL missed its primary endpoint, gross margins were lower than expected, and management flagged added Q4 costs from G-MELT, clinical programs and TYRVAYA integration, while some product performance such as BYOOVIZ was still early and dependent on reimbursement follow-through.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 75.4%
- Shares Outstanding
- 37.53M
- Float Shares
- 28.28M
of shares held by institutions
234 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 2.96M | ▲ 216.26K |
| Opaleye Management Inc. | 2.40M | ▼ 432.23K |
| Vanguard Group Inc | 1.92M | ▲ 50.89K |
| Private Capital Management, LLC | 1.60M | ▲ 36.77K |
| Vanguard Capital Management LLC | 1.39M | ▼ 22.48K |
| State Street Corp | 1.02M | ▲ 84.95K |
| Deep Track Capital, LP | 969.00K | ▲ 969.00K |
| Geode Capital Management, LLC | 852.94K | ▼ 52.62K |
| Bamco Inc | 809.35K | ▲ 809.35K |
| Dimensional Fund Advisors LP | 721.80K | ▲ 54.76K |
| Jupiter Topco LLC | 579.13K | ▲ 579.13K |
| Marshall Wace, Llp | 451.08K | ▲ 81.64K |
Held by 221 ETFs
Biggest fund positions in HROW by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 14, 26 | Shojaei Amir | other | 11,250 |
| Aug 14, 26 | Shojaei Amir | other | 11,250 |
| Aug 14, 26 | Shojaei Amir | sell | 11,250 |
| Jun 18, 26 | Sternberg Perry J. | other | 5,248 |
| Jun 18, 26 | SILVERNAIL LAUREN P | other | 5,248 |
| Jun 18, 26 | Graves Adrienne L | other | 5,248 |
| May 18, 26 | Graves Adrienne L | buy | 1,000 |
| May 18, 26 | SILVERNAIL LAUREN P | buy | 1,000 |
| May 15, 26 | Shojaei Amir | other | 10,000 |
| May 14, 26 | BAUM MARK L | buy | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HROW coverage
Recent articles, reports, and earnings notes.
Want a deeper read on HROW?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Harrow: Strong Revenue Growth And Operating Leverage Ahead
seekingalpha.com · Nov 16
66,773 Shares of Harrow, Inc. $HROW Bought by Drive Wealth Management LLC
defenseworld.net · Nov 15
Harrow to Participate in Two Investor Conferences in November
globenewswire.com · Nov 12
Harrow, Inc. (HROW) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
Harrow Q3 Earnings Call Highlights
marketbeat.com · Nov 10
Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say
zacks.com · Nov 9
Harrow (HROW) Q3 Earnings Lag Estimates
zacks.com · Nov 9
Harrow Announces Third Quarter 2026 Financial Results
globenewswire.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
